" class="no-js "lang="en-US"> Immunovia - Medtech Alert
Sunday, February 05, 2023
Immunovia | Pharmtech Focus

Immunovia

About Immunovia

Immunovia

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see:

Related Story

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs

January 17 2023

Immunovia, the diagnostics company that has launched the world’s first blood test dedicated to the […]

The PanDIA-1 Study, for Early Detection of Pancreatic Cancer in Newly Onset Type 2 Diabetics, Moves Into Next Phase

June 30 2022

Immunovia today announced the PanDIA-1 study for the early detection of pancreatic cancer in newly […]

Immunovia Appoints Jeff Borcherding, Previously Chief Marketing Officer at Myriad Genetics, to Lead Immunovia's US Business

March 28 2022

Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Jeff Borcherding as CEO of its US subsidiary Immunovia, Inc. He […]